About Zinc finger and SCAN domain-containing protein 23
Zinc finger and SCAN domain-containing protein 23 (ZSCAN23) is a protein
from Homo sapiens identified by UniProt accession
Q3MJ62, 389 residues long.
MolForge cross-references it against 0 known binders and
61 disease associations.
Target properties
| Protein name | Zinc finger and SCAN domain-containing protein 23 |
|---|
| UniProt accession | Q3MJ62 |
|---|
| Gene | ZSCAN23 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 389 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (61)
Diseases linked to this target (Open Targets).
- erythrocyte count · score 0.33
- platelet crit · score 0.31
- rheumatoid arthritis · score 0.26
- multiple sclerosis · score 0.24
- reticulocyte count · score 0.21
- schizophrenia · score 0.20
- psoriasis · score 0.20
- reticulocyte measurement · score 0.18
- mean platelet volume · score 0.18
- HbA1c measurement · score 0.17
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q3MJ62-F1 | alphafold | PREDICTED | 64.65 | — |
Amino-acid sequence (389 residues)
MAITLTLQTA EMQEGLLAVK VKEEEEEHSC GPESGLSRNN PHTREIFRRR FRQFCYQESP GPREALQRLQ ELCHQWLRPE MHTKEQILEL LVLEQFLTIL PEELQAWVRQ HRPVSGEEAV TVLEDLEREL DDPGEQVLSH AHEQEEFVKE KATPGAAQES SNDQFQTLEE QLGYNLREVC PVQEIDGKAG TWNVELAPKR EISQEVKSLI QVLGKQNGNI TQIPEYGDTC DREGRLEKQR VSSSVERPYI CSECGKSFTQ NSILIEHQRT HTGEKPYECD ECGRAFSQRS GLFQHQRLHT GEKRYQCSVC GKAFSQNAGL FHHLRIHTGE KPYQCNQCNK SFSRRSVLIK HQRIHTGERP YECEECGKNF IYHCNLIQHR KVHPVAESS
Explore Zinc finger and SCAN domain-containing protein 23 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets